The islet cell antibody test, or ICA, was the original autoantibody marker for type 1 diabetes and uses indirect immunofluorescence on frozen pancreatic tissue sections to detect autoantibodies in serum that bind pancreatic islet cells. It is positive in 70 to 80 percent of new-onset T1D but has been largely superseded by molecular-target-specific tests — GAD-65, IA-2, and ZnT8 — that are more standardized and reproducible. Understanding ICA is mostly useful for interpreting older medical records and for context on how the modern T1D antibody panel evolved.
What ICA Is and Where It Came From
In 1974, Gianfranco Bottazzo and colleagues at the Middlesex Hospital in London reported that the serum of some patients with newly diagnosed type 1 diabetes contained antibodies that bound pancreatic islet cells on frozen sections — visible under a fluorescence microscope after staining with a fluorescent secondary antibody. This was the first autoimmune marker for type 1 diabetes and ushered in the modern understanding of T1D as an autoimmune disease.
The assay works as follows:
- A frozen section of human or monkey pancreas is placed on a microscope slide
- The patient’s serum (containing any autoantibodies) is overlaid and incubated
- The slide is washed, then a fluorescent anti-human-IgG secondary antibody is applied
- Under a fluorescence microscope, islets fluoresce wherever the patient’s antibodies have bound
- The intensity is read by eye and quantified in Juvenile Diabetes Foundation (JDF) units against reference standards
The molecular targets the antibodies bind to are now known to include GAD-65, IA-2, ZnT8, and others — what ICA measures is the composite of all anti-islet antibodies in the patient’s blood.
Sensitivity by Population
| Population | ICA positivity rate | Notes |
|---|---|---|
| New-onset pediatric T1D | 70 to 80 percent | Highest sensitivity in children |
| New-onset adult T1D | 60 to 70 percent | Slightly lower than pediatric |
| LADA | 30 to 50 percent | Less sensitive than GAD-65 in this group |
| Long-standing T1D | 20 to 50 percent | Titers wane over years |
| Type 2 diabetes | 3 to 5 percent | Most positives represent missed LADA |
| First-degree relatives of T1D | 3 to 6 percent | Historical TrialNet predecessor screen |
| General population | 1 to 2 percent | Lower specificity than IA-2 or ZnT8 |
JDF Units and Interpretation
| JDF units | Interpretation | Clinical context |
|---|---|---|
| Less than 5 | Negative | No detectable islet autoimmunity |
| 5 to 10 | Borderline | Repeat; correlate with specific antibodies |
| 10 to 20 | Low positive | Mild islet autoimmunity |
| 20 to 80 | Moderate positive | Substantial autoimmunity; high T1D probability |
| Greater than 80 | High positive | Aggressive autoimmune diabetes |
JDF unit thresholds vary across laboratories. Always interpret against the lab’s own cutoff and reference range.
Why ICA Was Replaced
| Limitation of ICA | Advantage of modern panel |
|---|---|
| Subjective reading by microscopist | Quantitative ECLIA or ELISA |
| Requires frozen human/monkey pancreas | Uses recombinant defined antigens |
| Inter-lab variability | Standardized via DASP/IASP programs |
| Single composite result | Individual antigen-specific results |
| Cannot be automated | Fully automated |
| Specificity around 95 percent | Specificity greater than 98 percent (per antibody) |
| Ethical/supply issues with primate tissue | No tissue source dependency |
When ICA Might Still Be Used
- Research studies with historical cohorts: ongoing analyses of pre-1990s samples often used ICA originally and rerun in parallel for comparability.
- Reinterpreting older medical records: patients with a 30- or 40-year-old “ICA-positive” diagnosis can have that result understood in the modern context.
- International settings without access to recombinant assays: some centers in resource-limited settings may still perform ICA.
- Reference laboratory backup: a few reference labs still offer ICA, occasionally useful when the modern panel is negative but T1D suspicion remains high.
- Investigation of unusual cases: some patients have islet autoantibodies that target less-characterized antigens not in the standard panel — ICA may still detect these.
The Multiple-Autoantibody Concept
Although ICA itself has been retired in most clinical settings, the principle it established — that having any anti-islet autoimmunity predicts T1D — has evolved into the modern multiple-autoantibody concept:
| Number of positive antibodies | 5-year progression to T1D (in relatives) |
|---|---|
| 0 | Less than 1 percent |
| 1 | 10 to 20 percent |
| 2 | 40 to 60 percent |
| 3 or more | 70 to 80 percent |
In effect, what ICA used to measure as a composite is now measured as the count and pattern of individual specific antibodies.
How to Order Islet-Cell Antibody Testing Today
When a clinician orders “islet cell antibodies” today, they usually mean the modern panel:
- GAD-65 antibodies (glutamic acid decarboxylase)
- IA-2 antibodies (insulinoma-associated antigen 2, also ICA-512)
- ZnT8 antibodies (zinc transporter 8)
- Anti-insulin antibodies (only useful before insulin therapy is started)
Most US commercial labs (Quest, Labcorp, Mayo, ARUP) bundle these as a “Type 1 Diabetes Autoantibody Panel.” If you specifically need the classic ICA immunofluorescence test, you may need to send to a research reference laboratory or specialty center.
Limitations and Pitfalls (Classic ICA)
- Subjective reading: different microscopists read the same slide differently.
- Sensitivity drops with sample storage: antibody activity can degrade in long-stored serum.
- Limited availability: few US labs still run the test.
- No molecular specificity: a positive ICA does not tell you which antigen is the target.
- Cost and turnaround: ICA testing tends to be slower and pricier than the molecular panel.
What to Expect From Your Doctor
If you have new-onset diabetes and the clinical picture suggests possible autoimmune disease, expect your provider to order:
- A modern T1D autoantibody panel (GAD-65, IA-2, ZnT8, sometimes anti-insulin) rather than classic ICA
- Fasting and possibly stimulated c-peptide to gauge beta-cell function
- Confirmation of diabetes status with A1C and fasting glucose
- Possibly thyroid function and celiac antibodies, since associated autoimmunity is common
If you see “ICA” on an older medical record without further detail, ask whether it referred to the classic immunofluorescence assay or to a panel of the modern antibody tests.
Related Reading
See our broader guides on detection of prediabetes, GAD-65 antibody testing, IA-2 antibody testing, ZnT8 antibody testing, and c-peptide.
The Bottom Line
The islet cell antibody test was the original autoimmune marker for type 1 diabetes and a foundational discovery in modern diabetes immunology. It is positive in 70 to 80 percent of new-onset T1D but has been largely retired in clinical practice because the molecular-target-specific assays (GAD-65, IA-2, ZnT8) are more standardized, reproducible, and informative. If you see “islet cell antibodies” ordered today, it is almost always shorthand for the modern multi-antibody panel rather than the classic immunofluorescence test. The conceptual descendant of ICA — the multiple-autoantibody approach — remains a powerful tool for diagnosing and risk-stratifying autoimmune diabetes. Talk to your endocrinologist about which specific panel is right for your situation.
